Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients
Primary Purpose
Insomnia, Cardiovascular Diseases
Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
CBT-I
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia
Eligibility Criteria
Inclusion Criteria:
- Sleep disturbance as indicated by a score on the Insomnia Severity Index (ISI) of 8 or above.
- Enrolled in the cardiac rehabilitation program offered by the University of Ottawa Heart Institute.
- Willing to be randomized.
- Willing to wear a monitor that tracks sleep and physical activity.
Exclusion Criteria:
- Untreated or undiagnosed obstructive sleep apnea (as per standard cardiac rehabilitation intake assessment, patients with a score of 5 or above on the STOP-BANG (a brief assessment for sleep apnea) will be referred for a sleep assessment by a cardiac rehabilitation physician).
- Unable to converse in English (i.e., while patient materials and questionnaires will be offered in both English and French, the intervention is only offered in English).
- Unable to provide written, informed consent.
- Unable to attend 6 weeks of onsite CBT-I intervention.
Sites / Locations
- University of Ottawa Heart Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
CBT-I
Wait-list control
Arm Description
Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
Outcomes
Primary Outcome Measures
Sleep Quality
Sleep quality will be measured using the Consensus Sleep Diary.
Secondary Outcome Measures
Sleep Symptoms
Sleep symptoms will be measured using the Insomnia Severity Index
Sleepiness
The widely used Epworth Sleepiness Scale will be used to measure levels of sleepiness .experienced by patients
Activity
Participants will wear an ActiGraph GTX3 accelerometer (ActiGraph, Pensacola, Florida) to assess sleep and physical activity
Mental Health
Both symptoms and severity of anxiety and depression will be measured
Quality of life
Patient quality of life will be measured using the 36-item short-form health survey (SF-36; version 1)
Cardiovascular Risk Factors
Cardiovascular disease diagnosis, fasting blood glucose concentration, triglycerides, glycated hemoglobin (HbA1c), cholesterol (High-density lipoprotein ratio
Full Information
NCT ID
NCT03250468
First Posted
July 27, 2017
Last Updated
April 20, 2020
Sponsor
Ottawa Heart Institute Research Corporation
1. Study Identification
Unique Protocol Identification Number
NCT03250468
Brief Title
Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients
Official Title
Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Terminated
Why Stopped
Poor follow/up rates and data.
Study Start Date
April 19, 2018 (Actual)
Primary Completion Date
February 28, 2020 (Actual)
Study Completion Date
March 2, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ottawa Heart Institute Research Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Research aims:
To determine if participation in a group-based cognitive behavioural therapy intervention (CBT-I) intervention results in improved sleep quality.
To determine if participation in a group-based CBT-I intervention results in improved cardiovascular disease risk factors, and if the CBT-I intervention moderates that relationship.
Detailed Description
Cardiovascular disease affects 5% of the population and almost 20% of those meet the criteria for insomnia; twice as many as in the general population. Patients with cardiovascular disease and insomnia have been found to have elevated rates of anxiety and depression, which in turn places individuals at further cardiovascular risk via physiological pathways like increased blood pressure and/or vascular inflammation. Further, insomnia has been linked with negative health outcomes that exacerbate risk, including obesity, hypertension, and future acute myocardial infarction. Given the negative impact of poor sleep on cardiac health, some have argued that insomnia should now be included in the top 10 modifiable risk factors for cardiovascular disease.
Currently the best treatment for insomnia is a group-based cognitive behavioural therapy intervention (CBT-I); this intervention is more effective than pharmacotherapy. Evidence shows that CBT-I produces significant improvements after 6 weeks of intervention and improvements continue over the long term. This intervention program includes specific cognitive therapy exercises aimed at maladaptive thoughts about sleep, behaviour change techniques, and relaxation strategies (e.g., mindfulness, deep breathing); it also provides a supportive environment for individuals to discuss their sleep difficulties, allowing them to feel normalized and less isolated. For most people with insomnia however, their disorder goes untreated, leaving individuals at higher risk for affective disorders (e.g., depression), cardiovascular disease, and poorer quality of life. This lack of treatment is widespread and systemic; patients who want help with insomnia face a dearth of information about treatment, actual access to treatment and affordable services.
The proposed study is the first evaluation of a comprehensive CBT-I intervention designed for cardiac patients. Of note, the proposed study will be the first to evaluate the impact of this intervention on cardiovascular outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Cardiovascular Diseases
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CBT-I
Arm Type
Experimental
Arm Description
Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
Arm Title
Wait-list control
Arm Type
No Intervention
Arm Description
The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
Intervention Type
Behavioral
Intervention Name(s)
CBT-I
Intervention Description
Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
Primary Outcome Measure Information:
Title
Sleep Quality
Description
Sleep quality will be measured using the Consensus Sleep Diary.
Time Frame
Through study completion, up to 3 months
Secondary Outcome Measure Information:
Title
Sleep Symptoms
Description
Sleep symptoms will be measured using the Insomnia Severity Index
Time Frame
Through study completion, up to 3 months
Title
Sleepiness
Description
The widely used Epworth Sleepiness Scale will be used to measure levels of sleepiness .experienced by patients
Time Frame
Through study completion, up to 3 months
Title
Activity
Description
Participants will wear an ActiGraph GTX3 accelerometer (ActiGraph, Pensacola, Florida) to assess sleep and physical activity
Time Frame
Through study completion, up to 3 months
Title
Mental Health
Description
Both symptoms and severity of anxiety and depression will be measured
Time Frame
Through study completion, up to 3 months
Title
Quality of life
Description
Patient quality of life will be measured using the 36-item short-form health survey (SF-36; version 1)
Time Frame
Through study completion, up to 3 months
Title
Cardiovascular Risk Factors
Description
Cardiovascular disease diagnosis, fasting blood glucose concentration, triglycerides, glycated hemoglobin (HbA1c), cholesterol (High-density lipoprotein ratio
Time Frame
Through study completion, up to 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Sleep disturbance as indicated by a score on the Insomnia Severity Index (ISI) of 8 or above.
Enrolled in the cardiac rehabilitation program offered by the University of Ottawa Heart Institute.
Willing to be randomized.
Willing to wear a monitor that tracks sleep and physical activity.
Exclusion Criteria:
Untreated or undiagnosed obstructive sleep apnea (as per standard cardiac rehabilitation intake assessment, patients with a score of 5 or above on the STOP-BANG (a brief assessment for sleep apnea) will be referred for a sleep assessment by a cardiac rehabilitation physician).
Unable to converse in English (i.e., while patient materials and questionnaires will be offered in both English and French, the intervention is only offered in English).
Unable to provide written, informed consent.
Unable to attend 6 weeks of onsite CBT-I intervention.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heather Tulloch, Ph.D
Organizational Affiliation
Clinical, Health, and Rehabilitation Psychologist
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y4W7
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients
We'll reach out to this number within 24 hrs